A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation - PubMed (original) (raw)
Clinical Trial
. 2005 Jul;48(7):1416-23.
doi: 10.1007/s10350-005-0052-6.
Affiliations
- PMID: 15933795
- DOI: 10.1007/s10350-005-0052-6
Clinical Trial
A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation
Damián García-Olmo et al. Dis Colon Rectum. 2005 Jul.
Abstract
Purpose: The effective management of fistulas in patients with Crohn's disease presents an extremely challenging problem. Mesenchymal adult stem cells extracted from certain tissues, such as adipose tissue, can differentiate into various cell types. Therefore, we have tried to use such cells to stimulate healing of Crohn's fistulas.
Methods: We designed a prospective Phase I clinical trial, involving five patients with Crohn's disease, to test the feasibility and safety of autologous stem cells transplantation in the treatment of fistulas. We also studied the expression of various cell markers and the growth rates of the lipoaspirate-derived cells that were used for transplantation.
Results: One patient was excluded because of bacterial contamination of cultured cells. We inoculated nine fistulas in four patients with autologous adipose tissue-derived stem cells at Passage 3 or earlier. Eight inoculated fistulas were followed weekly for at least eight weeks. In six fistulas, the external opening was covered with epithelium at the end of Week 8, and, thus, these fistulas were considered healed (75 percent). In the other two fistulas, there was only incomplete closure of the external opening, with a decrease in output flow (not healed; 25 percent). No adverse effects were observed in any patient at the end of the follow-up period (minimum follow-up,12 months; maximum follow-up, 30 months; follow-up average, 22 months).
Conclusions: To our knowledge, this is the first report of a clinical trial of cell therapy using autologous stem cells obtained from a lipoaspirate. Our results indicate that our protocol is feasible and safe for the treatment of fistulas in Crohn's disease. The number of patients included and the uncontrolled nature of Phase I clinical trials do not allow demonstration of the effectiveness of the treatment. However, the results of the present study encourage to perform further studies in Phase II.
Similar articles
- Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial.
Garcia-Olmo D, Herreros D, Pascual I, Pascual JA, Del-Valle E, Zorrilla J, De-La-Quintana P, Garcia-Arranz M, Pascual M. Garcia-Olmo D, et al. Dis Colon Rectum. 2009 Jan;52(1):79-86. doi: 10.1007/DCR.0b013e3181973487. Dis Colon Rectum. 2009. PMID: 19273960 Clinical Trial. - Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease.
Ciccocioppo R, Bernardo ME, Sgarella A, Maccario R, Avanzini MA, Ubezio C, Minelli A, Alvisi C, Vanoli A, Calliada F, Dionigi P, Perotti C, Locatelli F, Corazza GR. Ciccocioppo R, et al. Gut. 2011 Jun;60(6):788-98. doi: 10.1136/gut.2010.214841. Epub 2011 Jan 21. Gut. 2011. PMID: 21257987 - Collagen fistula plug for the treatment of anal fistulas.
Ky AJ, Sylla P, Steinhagen R, Steinhagen E, Khaitov S, Ly EK. Ky AJ, et al. Dis Colon Rectum. 2008 Jun;51(6):838-43. doi: 10.1007/s10350-007-9191-2. Epub 2008 Mar 11. Dis Colon Rectum. 2008. PMID: 18330649 - Mesenchymal Stem Cells to Treat Crohn's Disease with Fistula.
Zhang XM, Zhang YJ, Wang W, Wei YQ, Deng HX. Zhang XM, et al. Hum Gene Ther. 2017 Jul;28(7):534-540. doi: 10.1089/hum.2016.095. Hum Gene Ther. 2017. PMID: 28132518 Review. - Overview of stem cell therapy for Crohn's disease.
Dryden GW. Dryden GW. Expert Opin Biol Ther. 2009 Jul;9(7):841-7. doi: 10.1517/14712590902956615. Expert Opin Biol Ther. 2009. PMID: 19527107 Review.
Cited by
- Adipose-derived mesenchymal stem cells alleviate TNBS-induced colitis in rats by influencing intestinal epithelial cell regeneration, Wnt signaling, and T cell immunity.
Gao JG, Yu MS, Zhang MM, Gu XW, Ren Y, Zhou XX, Chen D, Yan TL, Li YM, Jin X. Gao JG, et al. World J Gastroenterol. 2020 Jul 14;26(26):3750-3766. doi: 10.3748/wjg.v26.i26.3750. World J Gastroenterol. 2020. PMID: 32774055 Free PMC article. - Gastro-intestinal autoimmunity: preclinical experiences and successful therapy of fistulizing bowel diseases and gut Graft versus host disease by mesenchymal stromal cells.
Voswinkel J, Francois S, Gorin NC, Chapel A. Voswinkel J, et al. Immunol Res. 2013 Jul;56(2-3):241-8. doi: 10.1007/s12026-013-8397-8. Immunol Res. 2013. PMID: 23564182 Review. - Two phase I/II clinical trials for the treatment of urinary incontinence with autologous mesenchymal stem cells.
Garcia-Arranz M, Alonso-Gregorio S, Fontana-Portella P, Bravo E, Diez Sebastian J, Fernandez-Santos ME, Garcia-Olmo D. Garcia-Arranz M, et al. Stem Cells Transl Med. 2020 Dec;9(12):1500-1508. doi: 10.1002/sctm.19-0431. Epub 2020 Aug 31. Stem Cells Transl Med. 2020. PMID: 32864818 Free PMC article. Clinical Trial. - Assay validation for the assessment of adipogenesis of multipotential stromal cells--a direct comparison of four different methods.
Aldridge A, Kouroupis D, Churchman S, English A, Ingham E, Jones E. Aldridge A, et al. Cytotherapy. 2013 Jan;15(1):89-101. doi: 10.1016/j.jcyt.2012.07.001. Cytotherapy. 2013. PMID: 23260089 Free PMC article. - Adipose-Derived Regenerative Cell Injection Therapy for Postprostatectomy Incontinence: A Phase I Clinical Study.
Choi JY, Kim TH, Yang JD, Suh JS, Kwon TG. Choi JY, et al. Yonsei Med J. 2016 Sep;57(5):1152-8. doi: 10.3349/ymj.2016.57.5.1152. Yonsei Med J. 2016. PMID: 27401646 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical